Table 1.

Patient and Transplant Characteristics

Total number of patients	191
Median age at diagnosis, years (range)	59 (33 – 76)
Year of Diagnosis (Median 2006)
1992–2005	89 (47%)
2006 and later	102 (53%)
Male gender, no. (%)	142 (74%)
Stage, at diagnosis
I/II	3(2%)
III	20 (10%)
IV	168 (88%)
B Symptoms, at diagnosis	36 (19%)
Bone marrow involvement, at diagnosis	149 (78%)
Extranodal involvement, at diagnosis	67 (35%)
Blastoid variant	16 (8%)
MIPI (n=131)a
Low risk	63 (48%)
Intermediate risk	42 (32%)
High risk	26 (20%)
High-dose cytarabine pre-ASCT, no. (%)b	106 (56%)
Rituximab pre-ASCT, no. (%)	175 (92%)
No. or regimens pre-ASCT, no. (%)
1	128 (67%)
2	48 (25%)
3	15 (8%)
Median time from diagnosis to ASCT, months (range)	8 (4 – 105)
Year of Transplant (Median 2007)
1997–2006	88 (46%)
2007 and later	103 (54%)
Disease status at ASCT, no. (%)
CR1	144 (75%)
PR1	28 (15%)
CR2/PR2/PR3	19 (10%)
Conditioning, no. (%)
Chemotherapy only	101 (53%)
Radiation-based	90 (47%)
Conditioning, no. (%)
BEAM	54 (28%)
CBV	47 (25%)
TBI/VP/CY	32 (17%)
Z-BEAM	49 (26%)
High-Z	9 (5%)
Rituximab maintenance, no. (%)
375mg/m2 weekly × 4 every 6 mos. for 2 yrs.	46 (24%)
375mg/m2 every 2 mos. for 2 yrs.	16 (8%)
375mg/m2 every 3 mos. for 2 yrs.	13 (7%)
None	116 (61%)
Median follow-up post-ASCT, yrs. (range)c	6.3 (2.1 – 17.8)

Abbreviations: CR, complete remission; ASCT, high-dose therapy; MIPI, mantle cell lymphoma International prognostic index; PR, partial remission; BEAM, carmustine, etoposide, cytarabine, melphalan; CBV, cyclophosphamide, carmustine, etoposide; TBI/VP/CY, total body irradiation, etoposide, cyclophosphamide; Z-BEAM, ibritumomab tiuxetan, carmustine, etoposide, cytarabine, melphalan; High-Z, ibritumomab tiuxetan, cyclophosphamide, etoposide

^aData not available for all patients.

^bPatients treated with high-dose cytarabine received Hyper-CVAD (n=93), MaxiCHOP (n=10), or both (n=3).

^cSurviving patients (n=119).